TITLE

Clinical efficacy of anti-pneumococcal vaccination in patients with COPD

AUTHOR(S)
Alfageme, I.; Vazquez, R.; Reyes, N.; Muñoz, J.; Fernández, A.; Hernandez, M.; Merino, M.; Perez, J.; Lima, J.
PUB. DATE
March 2006
SOURCE
Thorax;Mar2006, Vol. 61 Issue 3, p189
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: A study was undertaken to evaluate the clinical efficacy of the 23-valent pneumococcal polysaccharide vaccine (PPY) in immunocompetent patients with chronic obstructive pulmonary disease (COPD). Methods: A randomised controlled trial was carried out in 596 patients with COPD of mean (SD) age 65.8 (9.7) years, 298 of whom received PPV. The main outcome was radiographically proven community acquired pneumonia (CAP) of pneumococcal or unknown aetiology after a mean period of 979 days (range 20-1454). Results: There were 58 first episodes of CAP caused by pneumococcus or of unknown aetiology, 25 in the intervention group and 33 in the non-intervention group. Kaplan-Meier survival curves for CAP did not show significant differences between the intervention and non-intervention arms (log rank test=1.15, p=0.28) in the whole group of patients. The efficacy of PPV in all patients was 24% (95% CI -24 to 54; p = 0.333). In the subgroup aged <65 years the efficacy of PPV was 76% (95% CI 20 to 93; p = 0.013), while in those with severe functional obstruction (forced expiratory volume in 1 second <40%) it was 48% (95% CI -7 to 80; p=0.076). In younger patients with severe airflow obstruction the efficacy was 91% (95% CI 35 to 99; p = 0.002). There were only five cases of non-bacteraemic pneumococcal CAP, all in the non-intervention group (log rank test=5.03; p=0.025). Multivariate analysis gave a hazard ratio for unknown and pneumococcal CAP in the vaccinated group, adjusted for age, of 0.20 (95% CI 0.06 to 0.68; p=0.01). Conclusions: PPV is effective in preventing CAP in patients with COPD aged less than 65 years and in those with severe airflow obstruction. No differences were found among the other groups of patients with COPD.
ACCESSION #
20349780

 

Related Articles

  • Polysaccharide pneumococcal vaccination: new evidence. Hall, A. J. // Thorax;Mar2006, Vol. 61 Issue 3, p183 

    The article looks at the studies of polysaccharide pneumococcal vaccination in elderly or high risk populations. A study which is published in this issue of the journal examines whether the vaccine would prevent community acquired pneumonia in individuals with chronic obstructive airways...

  • Pneumococcal vaccination: time to move on? Proesmans, Marijke Johanna // European Journal of Pediatrics;Nov2010, Vol. 169 Issue 11, p1435 

    The author comments on a study focusing on the surveillance of pediatric invasive pneumococcal infections in a tertiary care pediatric center in Quebec after the government-sponsored introduction of pneumococcal conjugate vaccine-7 (PCV-7) for children up to age 5 in a 2+1 schedule for infants....

  • Summary of NACI Statement: Interim Recommendations on the Use of Pneumococcal Vaccines in Immunocompetent Adults 65 Years of Age and Older. Quach, C.; Baclic, O.; National Advisory Committee on Immunization (NACI) // Canada Communicable Disease Report;Dec2016, Vol. 42 Issue 12, p260 

    Background: Since 2015, pneumococcal 13-valent conjugate vaccine (PNEU-C-13) has been authorized for the prevention of invasive pneumococcal disease (IPD) and pneumococcal community-acquired pneumonia (CAP) in adults. Adults with immunocompromising conditions are still recommended...

  • COMMENTARY: Review: Trials of injectable pneumococcal vaccines do not show effectiveness in chronic obstructive pulmonary disease. McGeer, Allison // ACP Journal Club;Mar/Apr2007, Vol. 146 Issue 2, p36 

    The article presents the author's comment on a research study focusing on the role of injectable vaccines in the prevention of pneumococcal infection in patients with chronic obstructive pulmonary disease. The author says that although preventing these infections is clearly desirable, the study...

  • Pneumococcal Coinfection with Human Metapneumovirus. Madhi, Shabir A.; Ludewick, Herbert; Kuwanda, Locadiah; van Niekerk, Nadia; Cutland, Clare; Little, Tessa; Klugman, Keith P. // Journal of Infectious Diseases;5/1/2006, Vol. 193 Issue 9, p1236 

    Background. Infection with the newly discovered human metapneumovirus (hMPV) may lead to hospitalization of children with lower respiratory tract infection (LRTI), although the pathogenesis thereof remains to be elucidated. Methods. This hypothesis-generating study involved a cohort of children...

  • Impact of Pneumococcal Vaccination on Pneumonia Rates in Patients with COPD and Asthma. Lee, Todd A.; Weaver, Frances M.; Weiss, Kevin B. // JGIM: Journal of General Internal Medicine;Jan2007, Vol. 22 Issue 1, p62 

    BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) are included in several national pneumococcal vaccination recommendations whereas asthma patients are not. The objective of this study was to evaluate pneumonia-related hospitalization risk in patients with COPD or asthma and...

  • Efficacy of pneumococcal vaccination in adults: a meta-analysis. Huss, Anke; Scott, Pippa; Stuck, Andreas E.; Trotter, Caroline; Egger, Matthias // CMAJ: Canadian Medical Association Journal;1/6/2009, Vol. 180 Issue 1, p48 

    Background: Clinical trials and meta-analyses have produced conflicting results of the efficacy of unconjugated pneumococcal polysaccharide vaccine in adults. We sought to evaluate the vaccine's efficacy on clinical outcomes as well as the methodologic quality of the trials. Methods: We searched...

  • Immune Response to Pneumococcal Conjugate and Polysaccharide Vaccines in Otitis-Prone and Otitis-Free Children. Barnett, Elizabeth D.; Pelton, Stephen I.; Cabral, Howard J.; Eavey, Roland D.; Allen, Carole; Cunningham, Michael J.; McNamara, Eileen R.; Klein, Jerome O. // Clinical Infectious Diseases;7/1/99, Vol. 29 Issue 1, p191 

    Provides information on a study which compared responses to the pneumococcal conjugate vaccine (PCV) and pneumococcal polysaccharide vaccine to understand the roles of vaccines in the prevention of pneumococcal disease including otitis media. How the study was conducted; Results; Discussion of...

  • Protecting against invasive pneumococcal disease: Be wise--immunize! Squires, Susan G.; Spika, John S. // CMAJ: Canadian Medical Association Journal;10/06/98, Vol. 159 Issue 7, p826 

    Discusses invasive pneumococcal pneumonia. Characteristics; Treatment choices; Recommendations from the Canadian Immunization Guide; Introduction of pneumococcal vaccination programs for high-risk groups in Canada.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics